World's Best Scientists 2026 revealed!
Scott N. Gettinger

Scott N. Gettinger

D-Index & Metrics

Medicine

D-Index
88
Citations
65615
World Ranking
12879
National Ranking
6585

Overview

Scott N. Gettinger is affiliated with Yale University in the United States and has made significant contributions to the field of medicine, particularly focusing on oncology, pulmonary and respiratory medicine, cancer research, molecular biology, and radiology. Their research portfolio comprises over 212 publications in medicine, with more than 86 specifically addressing oncology and nearly 78 in pulmonary and respiratory medicine.

The scientist's work covers a range of topics primarily related to lung cancer, including treatments and mutations, cancer immunotherapy and biomarkers, lung cancer research studies, cancer genomics and diagnostics, lung cancer diagnosis and treatment, radiomics and machine learning in medical imaging, and colorectal cancer treatments and studies.

Frequent publication venues for Gettinger's research include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer Research
  • Annals of Oncology

Key recent papers authored or coauthored by Gettinger include:

  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (2022), published in Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021 (2021), published in Journal of the National Comprehensive Cancer Network
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (2021), published in Journal of Clinical Oncology
  • Non-Small Cell Lung Cancer, Version 4.2024 (2024), published in Journal of the National Comprehensive Cancer Network
  • Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial (2020), published in The Lancet Oncology

Frequent co-authors collaborating with Gettinger include:

  • Roy S. Herbst
  • Enriqueta Felip
  • D. Ross Camidge
  • Marcello Tiseo
  • Sarah B. Goldberg

Throughout their career, Scott N. Gettinger's work has engaged with multiple subfields with emphasis on oncology, pulmonary and respiratory medicine, and cancer research. Their contributions reflect a sustained focus on lung cancer-related studies, immunotherapy, biomarker analysis, and advances in medical imaging.

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

    Sarah B Goldberg;Scott N Gettinger;Amit Mahajan;Anne C Chiang

  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

    Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

  • Programmed death ligand-1 expression in non-small cell lung cancer.

    Vamsidhar Velcheti;Kurt A Schalper;Daniel E Carvajal;Valsamo K Anagnostou

  • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

    D. Ross Camidge;Hye Ryun Kim;Myung Ju Ahn;James Chih Hsin Yang

  • Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines

    David S. Ettinger;Douglas E. Wood;Charu Aggarwal;Dara L. Aisner

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    David S. Ettinger;David S. Ettinger;Douglas E. Wood;Douglas E. Wood;Dara L. Aisner;Wallace Akerley;Wallace Akerley

  • Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    Scott Gettinger;Jungmin Choi;Katherine Hastings;Anna Truini

  • Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

    Scott Gettinger;Leora Horn;David Jackman;David Spigel

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Angeliki M. Stamatouli;Zoe Quandt;Ana Luisa Perdigoto;Pamela L. Clark

  • Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

    Naiyer A. Rizvi;Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Julie R. Brahmer;Rosalyn A. Juergens

  • Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

    Rituparna Das;Rakesh Verma;Mario Sznol;Chandra Sekhar Boddupalli

  • Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

    Scott Gettinger;Naiyer A. Rizvi;Laura Qm Chow;Hossein Borghaei

  • Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

    Everett E. Vokes;N. Ready;E. Felip;L. Horn

Frequent Co-Authors

Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Roy S. Herbst
Roy S. Herbst Yale University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Leora Horn
Leora Horn Vanderbilt University Medical Center
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Corey J. Langer
Corey J. Langer University of Pennsylvania
Scott J. Antonia
Scott J. Antonia Duke University
Katerina Politi
Katerina Politi Yale University
Alice T. Shaw
Alice T. Shaw Harvard University
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a future in Medicine, there are diverse online degrees and accelerated options that can help you enter or advance within the healthcare field. Many aspiring professionals now seek flexibility through remote study, choosing programs designed for speed, accessibility, and specialized focus.

Those aiming to become advanced practitioners may look into the fastest dnp online program options available, which allow experienced nurses to achieve the highest clinical degree in a shorter timeframe. For those seeking flexible and more accessible pathways, dnp programs online offer curricula that can be tailored to different schedules and backgrounds.

If you are interested in starting your nursing career quickly, a 6 month lpn program online could be a fast-track entry point into the industry. Alternatively, those looking to specialize in mental health might explore the fastest psych np program paths for advanced study.

Exploring these related degrees helps you identify suitable career pathways in healthcare, opening doors to rewarding roles and helping address workforce needs within medicine.

Best Scientists Citing Scott N. Gettinger

Trending Scientists

Recently Published Articles